osteolabs
osteolabs GmbH, a diagnostic company applying its proprietary calcium isotope marker (CIM) technology for the early detection of calcium-related metabolic bone diseases affecting over one billion patients worldwide, has announced the publication of real-world evidence data from close to 3000 OsteoTest patient samples in the journal Bone.
The publication marks the first report on the real-world application of CIM in the serum and urine of 2960 patient samples in total according to the company. This study was conducted in collaboration with researchers at GEOMAR, the University Hospital Schleswig-Holstein, and the UCL Great Ormond Street Hospital.
osteolabs says the data demonstrates a strong correlation between CIM and various metabolic diseases affecting musculoskeletal metabolism. The company also says the results align in full accordance with earlier clinical validation data and the established CIM threshold values for bone calcium balance (BCaB).
“We are very excited about the results from this collaborative effort that have now culminated in a publication in Bone,” said Professor Anton Eisenhauer, a key inventor of the CIM technology and osteolabs’ Chief Scientific Officer. “This larger subset of routine clinical samples fully supports the potential for OsteoTest to qualify as a new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.”
In 2021, osteolabs founded osteolabs UK to expand access to its osteoporosis diagnostic technology.
